Effectiveness and Implementation of the HiBalance Program in Clinical Practice
Launched by KAROLINSKA INSTITUTET · Mar 29, 2016
Trial Information
Current as of May 15, 2025
Completed
Keywords
ClinConnect Summary
The clinical features of PD include progressive postural instability, hypokinesia, tremor and rigidity. It is therefore common that people with PD experience reduced balance and gait function, symptoms which can have far-reaching negative effects on their health and quality of life. Injurious falls and fear of falling are especially prevalent among those with PD, a factor which may partly explain why this group are less physically active than older people of a similar age without the diagnosis. Balance and gait training, on the other hand, have been shown effective in PD and also appear to ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed idiopathic Parkinson's Disease
- • Measured balance impairment (according to the mini-BESTest)
- • Hoehn and Yahr stages 2-3
- • Independent ambulator indoors without a walking aid
- Exclusion Criteria:
- • Cognitive impairment which hinders participation in group training
- • The presence of comorbidities which hinder safe participation in group training
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, Södermanland, Sweden
Patients applied
Trial Officials
Erika Franzén, PhD
Principal Investigator
Karolinska Institutet
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials